Double‐blind controlled trial of gabapentin in essential tremor
Identifieur interne : 005026 ( Main/Exploration ); précédent : 005025; suivant : 005027Double‐blind controlled trial of gabapentin in essential tremor
Auteurs : Rajesh Pahwa ; Kelly Lyons ; Jean P. Hubble ; Karen Busenbark ; J. Dierkes Rienerth ; Anokh Pahwa ; William C. KollerSource :
- Movement Disorders [ 0885-3185 ] ; 1998-05.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Homme.
English descriptors
- KwdEn :
- Acetates (adverse effects), Acetates (therapeutic use), Activities of Daily Living (classification), Aged, Amines, Anticonvulsant, Antiparkinson Agents (adverse effects), Antiparkinson Agents (therapeutic use), Chemotherapy, Cyclohexanecarboxylic Acids, Double blind study, Double-Blind Method, Doubleblind, Essential, Essential tremor, Female, Gabapentin, Human, Humans, Male, Middle Aged, Motor Skills (drug effects), Neurologic Examination (drug effects), Placebo, Treatment, Tremor, Tremor (drug therapy), Tremor (etiology), gamma-Aminobutyric Acid.
- MESH :
- chemical , adverse effects : Acetates, Antiparkinson Agents.
- chemical , therapeutic use : Acetates, Antiparkinson Agents.
- classification : Activities of Daily Living.
- drug effects : Motor Skills, Neurologic Examination.
- drug therapy : Tremor.
- etiology : Tremor.
- Aged, Amines, Cyclohexanecarboxylic Acids, Double-Blind Method, Female, Humans, Male, Middle Aged, gamma-Aminobutyric Acid.
Abstract
Gabapentin has been reported to be effective for essential tremor (ET) based on open‐label trials. We studied gabapentin (1800 mg/day) and placebo in a double‐blind crossover design in 20 ET patients. Eighteen patients completed the study and two patients dropped out as a result of adverse effects which resolved when the medication was discontinued. Tremor was assessed at baseline and after 2 weeks of gabapentin and placebo treatment. One patient was mildly improved and another was moderately improved with placebo. Similarly, one patient reported mild improvement and another patient had marked improvement with gabapentin. All the remaining patients either reported no change or were worse with both treatment arms. There was no significant difference for total tremor score, hand tremor score, handwriting scores, or pouring scores. Sickness Impact Profile scores were no different between placebo and gabapentin. Our results suggest that as an adjuvant therapy in ET, gabapentin has limited benefit.
Url:
DOI: 10.1002/mds.870130315
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 003294
- to stream Istex, to step Curation: 003294
- to stream Istex, to step Checkpoint: 003761
- to stream PubMed, to step Corpus: 004423
- to stream PubMed, to step Curation: 004423
- to stream PubMed, to step Checkpoint: 004454
- to stream Ncbi, to step Merge: 004F60
- to stream Ncbi, to step Curation: 004F60
- to stream Ncbi, to step Checkpoint: 004F60
- to stream Main, to step Merge: 007F38
- to stream PascalFrancis, to step Corpus: 003029
- to stream PascalFrancis, to step Curation: 003795
- to stream PascalFrancis, to step Checkpoint: 003035
- to stream Main, to step Merge: 008159
- to stream Main, to step Curation: 005026
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Double‐blind controlled trial of gabapentin in essential tremor</title><author><name sortKey="Pahwa, Rajesh" sort="Pahwa, Rajesh" uniqKey="Pahwa R" first="Rajesh" last="Pahwa">Rajesh Pahwa</name></author><author><name sortKey="Lyons, Kelly" sort="Lyons, Kelly" uniqKey="Lyons K" first="Kelly" last="Lyons">Kelly Lyons</name></author><author><name sortKey="Hubble, Jean P" sort="Hubble, Jean P" uniqKey="Hubble J" first="Jean P." last="Hubble">Jean P. Hubble</name></author><author><name sortKey="Busenbark, Karen" sort="Busenbark, Karen" uniqKey="Busenbark K" first="Karen" last="Busenbark">Karen Busenbark</name></author><author><name sortKey="Dierkes Rienerth, J" sort="Dierkes Rienerth, J" uniqKey="Dierkes Rienerth J" first="J." last="Dierkes Rienerth">J. Dierkes Rienerth</name></author><author><name sortKey="Pahwa, Anokh" sort="Pahwa, Anokh" uniqKey="Pahwa A" first="Anokh" last="Pahwa">Anokh Pahwa</name></author><author><name sortKey="Koller, William C" sort="Koller, William C" uniqKey="Koller W" first="William C." last="Koller">William C. Koller</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:E449637028FAC712D77D92C9673EAFD4A360544B</idno><date when="1998" year="1998">1998</date><idno type="doi">10.1002/mds.870130315</idno><idno type="url">https://api.istex.fr/document/E449637028FAC712D77D92C9673EAFD4A360544B/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">003294</idno><idno type="wicri:Area/Istex/Curation">003294</idno><idno type="wicri:Area/Istex/Checkpoint">003761</idno><idno type="wicri:doubleKey">0885-3185:1998:Pahwa R:double:blind:controlled</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:9613738</idno><idno type="wicri:Area/PubMed/Corpus">004423</idno><idno type="wicri:Area/PubMed/Curation">004423</idno><idno type="wicri:Area/PubMed/Checkpoint">004454</idno><idno type="wicri:Area/Ncbi/Merge">004F60</idno><idno type="wicri:Area/Ncbi/Curation">004F60</idno><idno type="wicri:Area/Ncbi/Checkpoint">004F60</idno><idno type="wicri:doubleKey">0885-3185:1998:Pahwa R:double:blind:controlled</idno><idno type="wicri:Area/Main/Merge">007F38</idno><idno type="wicri:source">INIST</idno><idno type="RBID">Pascal:98-0262022</idno><idno type="wicri:Area/PascalFrancis/Corpus">003029</idno><idno type="wicri:Area/PascalFrancis/Curation">003795</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">003035</idno><idno type="wicri:doubleKey">0885-3185:1998:Pahwa R:double:blind:controlled</idno><idno type="wicri:Area/Main/Merge">008159</idno><idno type="wicri:Area/Main/Curation">005026</idno><idno type="wicri:Area/Main/Exploration">005026</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Double‐blind controlled trial of gabapentin in essential tremor</title><author><name sortKey="Pahwa, Rajesh" sort="Pahwa, Rajesh" uniqKey="Pahwa R" first="Rajesh" last="Pahwa">Rajesh Pahwa</name><affiliation><wicri:noCountry code="subField">University of Kansas Medical Center</wicri:noCountry></affiliation></author><author><name sortKey="Lyons, Kelly" sort="Lyons, Kelly" uniqKey="Lyons K" first="Kelly" last="Lyons">Kelly Lyons</name><affiliation><wicri:noCountry code="subField">University of Kansas Medical Center</wicri:noCountry></affiliation></author><author><name sortKey="Hubble, Jean P" sort="Hubble, Jean P" uniqKey="Hubble J" first="Jean P." last="Hubble">Jean P. Hubble</name><affiliation><wicri:noCountry code="subField">Ohio State University</wicri:noCountry></affiliation></author><author><name sortKey="Busenbark, Karen" sort="Busenbark, Karen" uniqKey="Busenbark K" first="Karen" last="Busenbark">Karen Busenbark</name><affiliation><wicri:noCountry code="subField">University of Kansas Medical Center</wicri:noCountry></affiliation></author><author><name sortKey="Dierkes Rienerth, J" sort="Dierkes Rienerth, J" uniqKey="Dierkes Rienerth J" first="J." last="Dierkes Rienerth">J. Dierkes Rienerth</name><affiliation><wicri:noCountry code="subField">Ohio State University</wicri:noCountry></affiliation></author><author><name sortKey="Pahwa, Anokh" sort="Pahwa, Anokh" uniqKey="Pahwa A" first="Anokh" last="Pahwa">Anokh Pahwa</name><affiliation><wicri:noCountry code="subField">University of Kansas Medical Center</wicri:noCountry></affiliation></author><author><name sortKey="Koller, William C" sort="Koller, William C" uniqKey="Koller W" first="William C." last="Koller">William C. Koller</name><affiliation><wicri:noCountry code="subField">University of Kansas Medical Center</wicri:noCountry></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="1998-05">1998-05</date><biblScope unit="vol">13</biblScope><biblScope unit="issue">3</biblScope><biblScope unit="page" from="465">465</biblScope><biblScope unit="page" to="467">467</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">E449637028FAC712D77D92C9673EAFD4A360544B</idno><idno type="DOI">10.1002/mds.870130315</idno><idno type="ArticleID">MDS870130315</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Acetates (adverse effects)</term><term>Acetates (therapeutic use)</term><term>Activities of Daily Living (classification)</term><term>Aged</term><term>Amines</term><term>Anticonvulsant</term><term>Antiparkinson Agents (adverse effects)</term><term>Antiparkinson Agents (therapeutic use)</term><term>Chemotherapy</term><term>Cyclohexanecarboxylic Acids</term><term>Double blind study</term><term>Double-Blind Method</term><term>Doubleblind</term><term>Essential</term><term>Essential tremor</term><term>Female</term><term>Gabapentin</term><term>Human</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Motor Skills (drug effects)</term><term>Neurologic Examination (drug effects)</term><term>Placebo</term><term>Treatment</term><term>Tremor</term><term>Tremor (drug therapy)</term><term>Tremor (etiology)</term><term>gamma-Aminobutyric Acid</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Acetates</term><term>Antiparkinson Agents</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Acetates</term><term>Antiparkinson Agents</term></keywords><keywords scheme="MESH" qualifier="classification" xml:lang="en"><term>Activities of Daily Living</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Motor Skills</term><term>Neurologic Examination</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Tremor</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Tremor</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Amines</term><term>Cyclohexanecarboxylic Acids</term><term>Double-Blind Method</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>gamma-Aminobutyric Acid</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Anticonvulsivant</term><term>Chimiothérapie</term><term>Essentiel</term><term>Etude double insu</term><term>Gabapentine</term><term>Homme</term><term>Traitement</term><term>Tremblement</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Gabapentin has been reported to be effective for essential tremor (ET) based on open‐label trials. We studied gabapentin (1800 mg/day) and placebo in a double‐blind crossover design in 20 ET patients. Eighteen patients completed the study and two patients dropped out as a result of adverse effects which resolved when the medication was discontinued. Tremor was assessed at baseline and after 2 weeks of gabapentin and placebo treatment. One patient was mildly improved and another was moderately improved with placebo. Similarly, one patient reported mild improvement and another patient had marked improvement with gabapentin. All the remaining patients either reported no change or were worse with both treatment arms. There was no significant difference for total tremor score, hand tremor score, handwriting scores, or pouring scores. Sickness Impact Profile scores were no different between placebo and gabapentin. Our results suggest that as an adjuvant therapy in ET, gabapentin has limited benefit.</div></front></TEI><affiliations><list></list><tree><noCountry><name sortKey="Busenbark, Karen" sort="Busenbark, Karen" uniqKey="Busenbark K" first="Karen" last="Busenbark">Karen Busenbark</name><name sortKey="Dierkes Rienerth, J" sort="Dierkes Rienerth, J" uniqKey="Dierkes Rienerth J" first="J." last="Dierkes Rienerth">J. Dierkes Rienerth</name><name sortKey="Hubble, Jean P" sort="Hubble, Jean P" uniqKey="Hubble J" first="Jean P." last="Hubble">Jean P. Hubble</name><name sortKey="Koller, William C" sort="Koller, William C" uniqKey="Koller W" first="William C." last="Koller">William C. Koller</name><name sortKey="Lyons, Kelly" sort="Lyons, Kelly" uniqKey="Lyons K" first="Kelly" last="Lyons">Kelly Lyons</name><name sortKey="Pahwa, Anokh" sort="Pahwa, Anokh" uniqKey="Pahwa A" first="Anokh" last="Pahwa">Anokh Pahwa</name><name sortKey="Pahwa, Rajesh" sort="Pahwa, Rajesh" uniqKey="Pahwa R" first="Rajesh" last="Pahwa">Rajesh Pahwa</name></noCountry></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 005026 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 005026 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:E449637028FAC712D77D92C9673EAFD4A360544B
|texte= Double‐blind controlled trial of gabapentin in essential tremor
}}
| This area was generated with Dilib version V0.6.23. |  |